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Abstract
Schizophrenia is characterized by increased behavioral and neurochemical responses to dopamine-releasing drugs.
This prompted the hypothesis of psychosis as a state of “endogenous” sensitization of the dopamine system although
the exact basis of dopaminergic disturbances and the possible role of prefrontal cortical regulation have remained
uncertain. To show that patients with first-episode psychosis release more dopamine upon amphetamine-stimulation
than healthy volunteers, and to reveal for the first time that prospective sensitization induced by repeated
amphetamine exposure increases dopamine-release in stimulant-naïve healthy volunteers to levels observed in
patients, we collected data on amphetamine-induced dopamine release using the dopamine D2/3 receptor agonist
radioligand [11C]-(+)-PHNO and positron emission tomography. Healthy volunteers (n= 28, 14 female) underwent a
baseline and then a post-amphetamine scan before and after a mildly sensitizing regimen of repeated oral
amphetamine. Unmedicated patients with first-episode psychosis (n= 21; 6 female) underwent a single pair of
baseline and then post-amphetamine scans. Furthermore, T1 weighted magnetic resonance imaging of the prefrontal
cortex was performed. Patients with first-episode psychosis showed larger release of dopamine compared to healthy
volunteers. After sensitization of healthy volunteers their dopamine release was significantly amplified and no longer
different from that seen in patients. Healthy volunteers showed a negative correlation between prefrontal cortical
volume and dopamine release. There was no such relationship after sensitization or in patients. Our data in patients
with untreated first-episode psychosis confirm the “endogenous sensitization” hypothesis and support the notion of
impaired prefrontal control of the dopamine system in schizophrenia.
Introduction
Several lines of evidence demonstrate increased sub-
cortical dopamine (DA) transmission in psychotic
patients with schizophrenia (SCZ). Positron emission
tomography (PET) studies show increased dopamine
synthesis capacity and heightened behavioral and neuro-
chemical responses towards DA-releasing compounds1–6.
The common mechanism of action of all antipsychotic
drugs—reducing DA transmission at postsynaptic D2/3
receptors—confirms the key role of DA signaling in psy-
chosis7. While the pathophysiological basis of DA dys-
function in SCZ remains unknown, current versions of
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the DA theory of SCZ8 posit that upstream pathogenic
factors converge on subcortical DA pathways to mediate
the expression and intensity of psychotic symptoms9–11.
Sensitization denotes a process by which repeated
exposure to a stimulus induces a progressive increase in
responses to the very same stimulus12,13. When repeatedly
administered, D-amphetamine (AMPH) induces beha-
vioral sensitization and a progressive amplification in
AMPH-induced DA release14–16. Since psychotic patients
show elevated responses to AMPH without any prior drug
exposure1, psychosis has been conceptualized as a state of
“endogenous sensitization”10,17,18. The prefrontal cortex
(PFC), origin of reciprocal regulatory connections to
subcortical DA neurons19, has often been found to be
structurally and functionally impaired in SCZ20,21. Earlier
studies have shown particularly strong relationships
between subcortical DA metabolism and the left-
hemispheric dorso-lateral PFC (DLPFC) and inferior
frontal gyrus (IFG) in SCZ and subjects at-risk mental
state for SCZ22,23. In order to collect experimental evi-
dence supporting this concept, we used PET and the DA
D2/3 receptor agonist radioligand (+)-4-propyl-
3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-
9-ol ([11C]-(+)-PHNO)24 for measuring AMPH-induced
changes in D2/3 receptor binding, semi-quantitative index
of DA release, in drug-naïve patients with first-episode
psychosis (FEP). Healthy volunteers (HV) were studied
before and after exposure to a mildly sensitizing regime of
repeated AMPH administration. In order to identify
upstream pathogenic mechanisms of psychotic hyperdo-
paminergia, we analyzed volumetric parameters in the
PFC for their relationship to indices of subcortical DA
release.
Materials and methods
All procedures of this study (Clinical Trial Registry:
EUDRACT 2010-019586-29) were approved by the ethics
committee of the Medical University of Vienna and per-
tinent federal regulatory authorities. After a test-retest
phase ensuring reliability of local [11C]-(+)-PHNO PET
imaging procedures (six male HV), 42 HV and 29 anti-
psychotic-naïve (or minimally exposed) patients with FEP
capable of providing informed consent were recruited
between 2013 and 2017; HV were required to be of good
health based on physical examination, history, ECG, and
laboratory results. Exclusion criteria comprised any intake
of drugs of abuse except nicotine, caffeine, and alcohol
(occasional use only), five or more stimulant exposures
lifetime, psychiatric disorders (evaluated with the DSM-IV
based M.I.N.I. questionnaire25), having a first-degree
relative with schizophrenia or bipolar disorder or having
any contraindications against receiving a PET, MRI or d-
amphetamine; in addition, FEP patients were required to
have a minimum Positive and Negative Symptom Scale
(PANSS26,27) score of 55 with >3 on at least two PANSS
psychosis items or >4 on one psychosis item; no or
minimal lifetime exposure to antipsychotics; no lifetime
exposure to antipsychotic depot preparations; no anti-
psychotics within two weeks prior to scanning (for details
see Supplemental Material). Diagnoses of FEP in SCZ
according to DSM-IV were independently made by at
least two experienced psychiatrists (N.M.; N.P-R., S.K., M.
W.). Three patients were previously exposed to olanza-
pine, aripiprazole, or quetiapine. Antipsychotics had been
discontinued at least two months prior to inclusion
without attaining a predefined threshold of two treatment
weeks or lifetime exposure up to 50mg haloperidol-
equivalent. Three patients had a history of antidepressant
treatment discontinued at least two months prior to
inclusion. During the study, eleven patients required
symptomatic treatment for psychomotor agitation or
insomnia (lorazepam 1–10mg or zolpidem 10mg
per day). Data sets (complete or partial) of 28+ 6 HV and
21 FEP patients entered final analysis (see Supplemental
Material and Supplementary Table 1 for full details).
Study setup and prospective sensitization
First, drug-naïve HV (HVUNSENS) underwent an
AMPH-free [11C]-(+)-PHNO PET scan (baseline1, PET1).
On a separate day less than five 5 days apart, a second
scan (PET2) was performed 90–120 min after oral
administration of 0.4 mg/kg body weight AMPH (Atten-
tin®, MEDICE Arzneimittel GmbH, Iserlohn, D), a time
point at which subjective effects are peaking and blood
levels are still rising (blood levels are highest after
3–4 h28). The AMPH dose was chosen according to
earlier studies showing that dosages between 0.3 and
0.5 mg/kg body weight induce reliable reductions in [11C]-
(+)-PHNO BPND values
29,30. The dose corresponds to a
low to medium dose used for treating attention deficit-
hyperactivity disorder in children. Administration of
AMPH at this same dose was repeated two more times at
intervals of two days. Two to four weeks thereafter, the
now sensitized HV (HVSENS) underwent another AMPH-
free scan (baseline2, PET3), and within five days, a fourth
scan (PET4) preceded by AMPH dose four (Fig. 1, lower
panel).
Patients with FEP received one baseline scan (PET1) and
one AMPH-scan (PET2; protocol as above). AMPH led to
temporary increases in heart rate and blood pressure
(Supplementary Fig. 1). Occasionally, participants repor-
ted mild headache and insomnia the night after AMPH
administration. Neither HV nor patients experienced any
serious AMPH-related adverse events.
[11C]-(+)-PHNO PET and MR imaging
[11C]-(+]-PHNO was synthesized as described earlier31.
Quality control was in accordance with European
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Pharmacopoeia. PET images were acquired on a GE
Advance scanner (General Electric Medical Systems,
Milwaukee, WI). Emission data were acquired over
90min after bolus-injection of 309 [81] MBq (mean [SD])
[11C]-(+)-PHNO. Raw data were reconstructed by
filtered-back projection to yield dynamic images in 15
consecutive one-minute frames followed by 15 five-
minute frames. With exception of two patients who
chose to terminate their participation early, all subjects
underwent T1 and proton density (PD) weighted 3 T
magnetic resonance (MR) imaging (see Supplemental
Material).
Behavioral and hormonal measurements
Subjective AMPH effects were recorded using the drug
effects questionnaire32 and the subjective states ques-
tionnaire (SSQ)33. The PANSS scale26 was administered
by certified raters for measuring baseline psychopathology
in FEP patients, the brief psychiatric rating scale (BPRS34)
was used to measure AMPH-induced changes in psy-
chopathology. Blood for serum AMPH levels was col-
lected at the beginning of PET scans. Heart rate, blood
pressure (systolic and diastolic were determined repeat-
edly before and during PET scans (see Supplemental
Material).
Image analysis
Analysis in regions of interest
Frame-wise motion correction and co-registration of
attenuation-corrected average PET images to T1-
weighted MRIs was performed using AFNI software.
PET images of two FEP patients who did not undergo MR
imaging (see above) were co-registered to normalized
[11C]-(+)-PHNO template images (one each for no-
intervention and AMPH scans) created by averaging spa-
tially normalized PET images (early and late low-contrast
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Fig. 1 Amphetamine (AMPH)-induced dopamine (DA) release and subjective AMPH effects in healthy volunteers before and after AMPH-
sensitization and in drug-free patients with first-episode psychosis (FEP). Upper panel: a AMPH-induced DA release in five subdivisions of the
basal ganglia (CAU Caudate, PUT Putamen, VST Ventral Striatum, GP Globus Pallidus, SNVTA substantia nigra/ventral-tegmental area) in healthy
volunteers before (HVUNSENS; sky-blue) and after prospective sensitization to AMPH (HVSENS; deep-blue), and in antipsychotic-naïve patients FEP (red).
Patients show larger AMPH-induced DA release than HVUNSENS. Prospective sensitization of HVUNSENS induced by repeated AMPH administration
amplifies DA release, such that the AMPH response in HVSENS no longer differs from FEP. b Statistical parametric maps displaying brain areas with the
largest sensitization-induced increases in DA-release. Peak effects (up to 60 percent increase) are found in VST (MNI coordinates x=−19, y=−16,
z=−10). c Subjective AMPH effects in HV undergoing prospective sensitization to AMPH. Repeated administration (four times; light to deep-blue) of
AMPH at low constant dose (0.3 mg/kg body weight) successfully induced sensitization as shown by the progressive increase in the AMPH response.
Patients with FEP (red; one administration of AMPH) displayed marked AMPH effects already at first contact with the drug. SSQ Subjective States
Questionnaire; MNI Montreal Neurologic Institute standard space; bars represent mean ± standard error of the mean; post-hoc two-tailed t-tests:
*p < 0.05, **p < 0.01). Lower panel: Study flowchart.
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frames omitted) of 15 HV. Individually optimized bilateral
regions of interest (ROIs) were obtained for the caudate
nucleus (CAU), putamen (PUT), ventral striatum (VST),
and cortical cerebellum (CER) using the automated image
analysis software ROMI35 as described elsewhere30. Since
automated algorithms provided no satisfactory ROI deli-
neation in globus pallidus (GP) and substantia nigra/
ventral tegmental area (SNVTA), GP and SN/VTA were
delineated manually by a single rater on individual PD MR
images (fused with PET images for aiding delineation of
SNVTA). ROI delineation was evaluated independently by
a second rater visually controlling for anatomical fit and
assessing outliers and time drift in ROI sizes. Decay-
corrected time–activity curves (TACs) were extracted
from the dynamic sequence. The simplified reference
tissue model (SRTM2)36,37 implemented in PMOD soft-
ware (Version 3.6; PMOD Technologies Ltd, Zurich,
Switzerland) was used to derive binding potential (BPND)
values in each ROI. Cerebellar cortex (CER) avoiding
midline structures served as reference region since it is
virtually devoid of DA D2/3 receptors in humans
38–40.
Relative AMPH-induced change in [11C]-(+)-PHNO BPND
binding was calculated as [(BPNDbaseline – BPNDAMPH)/
BPNDbaseline * 100] (ΔBPND; for the sake of simplicity hen-
ceforth designated “DA release”).
Parametric analysis
Voxel-wise BPND maps were calculated using the
PMOD 3.6 SRTM basis function implementation41. TACs
previously derived in CER (low-binding) and VST (high-
binding) were used to optimize iterative model fitting
procedures. Effects of AMPH and AMPH-sensitization
were analyzed using the AFNI programs 3dttest++
and 3dLME.
Volumetric analyses
T1-weighted MR images were processed using Free-
surfer 6.0 software (http://surfer.nmr.mgh.harvard.edu/).
Cortical gray voxels were allocated to a set of regions
predefined in the Destrieux atlas42 using a Bayesian
algorithm. Skull-stripping, gross accuracy of delineation,
and surface modeling were quality-controlled by visual
inspection of processed images.
Statistical analysis
The sample size of this study was planned according to
data collected with antagonist radioligands in sensitiza-
tion and patients with schizophrenia3–5,15. Statistical
analysis of [11C]-(+)-PHNO BPND values obtained in the
ROI-based analysis of [11C]-(+)-PHNO binding was car-
ried out using mixed linear models (MLM) as imple-
mented in SPSS 24.0 (SPSS 24.0; IBM Corp., Armonk,
NY) and R 12.0.1 (R Foundation for Statistical Comput-
ing, Vienna, Austria; https://www.r-project.org) software.
Analysis of differences in DA release (ΔBPND) between
HV before and after sensitization was carried out using
ΔBPND as dependent variable and group (FEP vs. HVUN-
SENS, and FEP vs. HVSENS, respectively) as fixed variable; ROI
was entered as random variable. For analyzing receptor
binding, BPND was entered as dependent variable, subject
status (HVUNSENS, HVSENS, FEP) as fixed between-group
factor, scan condition (AMPH yes/no) as fixed repeated
factor, and ROI as fixed or random repeated factor. MLM
analyses testing the effects of covariates (PFC volume
parameters) were carried out analogously. All main effects
and all relevant interactions were entered into the
respective models. The subject-identifier variable was
entered as random factor where appropriate. Two-tailed
t-tests (paired where appropriate) were used for post-hoc
tests after assuring normal distribution. Correlations were
calculated using Pearson product moment (r) or, if
appropriate, Spearman rank sum (rho) correlation coef-
ficients. Results confirming the main a-priori study
hypotheses (Figs. 1, 2) were not corrected for multiple
comparisons. More exploratory results (Figs. 3–5) were
carried out using ROI-based and parametric methods
(voxel-wise maps for PET images, vertex-wise analysis of
MR images) for independent confirmation. Results of the
ROI-based analysis on the relationship between PANSS
items and BPND values (Fig. 3; 30 PANSS items, 5 ROIs,
two hemispheres and on/off AMPH) and the relationship
between regional cortical volumes as implemented in
Freesurfer 6.0 software42 and ΔBPND (Fig. 4; 33 cortical
regions, 5 ROIs, two hemispheres; three groups) were
Bonferroni corrected, resulting in adjusted significance
levels of pcorr1= 0.00008 and pcorr2= 0.00005, respectively.
Results
DA release in FEP and sensitization
The concept of “endogenous sensitization” in psy-
chosis17 predicts that the difference in AMPH-induced
DA release between FEP patients and HV should dis-
appear or substantially diminish after HV are sensitized to
AMPH. Analysis of AMPH-induced changes in [11C]-
(+)-PHNO binding (ΔBPND) showed significant differ-
ences between unsensitized HV and FEP (HVUNSENS vs.
FEP: F(1;184.04)= 11.6, p= .0008: Fig. 1a). After HV were
sensitized, groups were no longer significantly different
(HVSENS vs. FEP: F(1;175.6))= 0.99, p= .32; Fig. 1a, Sup-
plementary Table 2). Including alcohol and nicotine
consumption and sex as covariates into the model did not
relevantly alter results (HVUNSENS vs. FEP: F(1;139.9)= 11.6,
p= 0.0008, see Supplemental Material for details). In
good agreement with the ROI-based analysis, parametric
ΔBPND maps showed the most robust effects of sensiti-
zation in the VST (Fig. 1b). Indicating behavioral sensi-
tization in HVSENS, repeated AMPH-administration
induced progressive enhancement of subjective AMPH
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effects up to levels observed in FEP (Fig. 1c, Supplemen-
tary Fig. 2).
Analysis of group differences and AMPH-effects at the
level of D2/3 receptor binding before sensitization ([
11C]-
(+)-PHNO BPND values by group, condition, and ROI)
showed significant two-way interactions between group
and condition (HVUNSENS/FEP * no-AMPH/AMPH:
F(1;305.7)= 9.9, p= .009), group and ROI (F(4;140)= 10.7,
p= 1.3 × 10−7), and a significant three-way interaction
between group, condition, and ROI (F(8;140)= 3.0, p
= .004).
The same model, when applied to FEP and HV after
sensitization, did no longer show a significant two-way
interaction between group and condition (F(1;275.8)= 0.6,
p= 0.42). However, the group*ROI (F(4;123)= 11.2, p=
9.4 × 10−8), and a group*condition* ROI interactions
remained significant, (F(8;123.1)= 5.5, p= 5 × 10
−5; Fig. 2a, b).
At least in part, this is due to the fact that irrespective of
AMPH pretreatment, D2/3 receptor binding was con-
sistently lower in FEP than in HVs in neo-striatal ROIs
(CAU, PUT, VST) but higher in GP (and trend-wise also
in SNVTA; Fig. 2b; Supplementary Table 3). Baseline D2/3
receptor binding and sensitization showed a significant
positive correlation for all regions in HV (see Supple-
mentary Fig. 3). An analysis of functional subdivisions of
the basal ganglia as previously published did not reflect
our findings (Supplementary Fig. 4).
Indices of DA release were positively correlated with
behavioral AMPH effects (see Supplemental Material). It
is known that benzodiazepines might interact with
dopamine neurotransmission43. Thus we compared DA
release between patients receiving benzodiazepines and
those who did not require sedation, we found no sig-
nificant difference (16 available datasets for calculating
DA release, 7 not receiving lorazepam, 9 receiving lor-
azepam; two-sided t-test p > 0.05 for all ROIs).
Fig. 2 Dopamine (DA) D2/3 receptor binding ([
11C]-(+)-PHNO BPND values) in scans without (PET1 and PET3) and with prior administration
of amphetamine (AMPH; PET2 and PET4). a Panels show binding in five subcortical regions of interest (ROIs; CAU, caudate; PUT, putamen; VST,
ventral striatum; GP, globus pallidus; SNVTA, substantia nigra/ventral-tegmental area) in healthy volunteers before (HVUNSENS; sky-blue) and after
AMPH sensitization (HVSENS; deep-blue) and in patients with first-episode psychosis (FEP; red). X-axis break between PET2 and PET3 in HV indicates a
scan-free interval (2–4 weeks) during prospective AMPH sensitization. All direct AMPH effects (PET1 vs. PET2 HVUNSENS and FEP, PET3 vs. PET4 HVsens)
were significant (paired t-tests p= 0.03–2.5 × 10−5; not marked). Note that AMPH sensitization led to a significant increase in D2/3 receptor binding
from PET1 to PET3 in VST. b Alternative representation of data shown in a highlighting systematic differences in D2/3 receptor binding across
conditions between HV and patients with FEP. D2/3 binding in FEP is lower than in HV in D2 receptor-rich neo-striatal regions (CAU, PUT, VST), while it
is elevated in D3 receptor-rich regions of the paleo-striatum (GP and SNVTA). Error bars represent 95% confidence intervals. *p < 0.05, **p < 0.01,
***p < 0.001, post-hoc two-tailed t-test.
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AMPH effects on psychopathology
With a mean [SD] PANSS score of 82.2 [6.9] (subscales
for positive, negative, and general SCZ symptoms: 21.4
[6.8], 20.1 [6.1], and 40.8 [9.4]), FEP patients were suf-
fering from acute psychosis of moderate to marked
severity at the time of PET scanning. Administration of
AMPH prompted a temporary increase in psychotic
symptoms. Symptoms returned to baseline after 3–4 h
without specific intervention. While positive symptoms of
SCZ (in particular hallucinations, delusions, and thought-
disorder) increased with AMPH, negative (especially
blunted affect and emotional withdrawal) and affective
symptoms (depressed mood) improved (Fig. 3a, b; Sup-
plementary Table 4). In contrast to earlier studies3–6,44–46
but in line with a recent study using the D2/3 receptor
agonist radioligand [11C]N-propyl-apomorphine ([11C]
NPA47), we did not observe significant relationships
between positive symptoms and DA release. However,
there were significant relationships between [11C]-
(+)-PHNO BPND values in the AMPH condition and
negative symptoms. Correlations were strongest in PUT
and driven mainly by the PANSS item N2 (“emotional
withdrawal”; right PUT: rho= 0.93, p= 7.7 × 10−8; Fig.
3c, d; Supplementary Fig. 5). Typical behavioral effects of
Fig. 3 Amphetamine (AMPH)-induced changes in psychopathology and relationship between [11C]-(+)-PHNO binding and emotional
withdrawal in patients with first-episode psychosis (FEP). a Changes in brief psychiatric rating scale (BPRS) positive and b negative symptom
scores at different time-points after AMPH administration in patients with FEP. Values were calculated as increase or decrease from baseline scores.
Bars represent mean ± standard error of the mean. Psychopathological changes did not require medical intervention and returned to baseline levels
shortly after PET scanning. c Correlation between ‘emotional withdrawal’ and [11C]-(+)-PHNO BPND values in the right putamen of patients with FEP.
d Voxel-wise analysis showing the correlation between severity of the negative SCZ symptom ‘emotional withdrawal’ (PANSS item N2) and [11C]-
(+)-PHNO BPND values in patients with FEP (pcorr < 0.01; t-max: 5.68 at MNI x=−21, y= 0, z=−11).
Fig. 4 Vertex-wise analysis on the relationship between sensitization in dopamine (DA) release (increase in amphetamine-induced
changes in [11C]-(+)-PHNO BPND values) and whole-cortex volumetric measures in healthy volunteers (HV). a The analysis identified largest
effects in a left-hemispheric cluster comprising the dorsolateral prefrontal cortex (BA46) and Broca’s area (BA 44 and 45; cluster thresholded at t=−4.3; peak
signal at MNI coordinates x= 6, y=−13, z=−7). b Positive relationship between sensitization of DA release and volume of the inferior frontal gyrus (IFG).
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AMPH in healthy volunteers included increased produc-
tion of speech, extraversion, alertness, and enhanced
energy.
PFC volume and subcortical DA release
Dysfunctional PFC-DA interactions are prime candi-
dates for “upstream” pathogenic mechanisms underlying
subcortical hyperdopaminergia in patients with SCZ.
Furthermore, brain circuits involved in cognitive func-
tions encompassing the PFC are often found to be com-
promised in patients with SCZ48. Thus we derived
volumetric parameters from MR images and, in a first
step, analyzed the relationship between indices of DA
release and overall PFC volume. Consistent with inhibi-
tion of DA release by the PFC19,22, we observed an inverse
relationship between PFC volume and DA release in
AMPH naïve HVUNSENS. After AMPH sensitization, the
association was lost or even reversed and more resembled
the pattern observed in FEP patients. An anatomically
unbiased vertex-wise analysis of the relationship between
sensitization of DA release in SNVTA (ΔBPND-SENS −
ΔBPND-UNSENS) and whole-cortex volumetric parameters
identified a left-hemispheric cluster spanning the
boundaries of middle and inferior frontal gyrus as main
driver of the whole-PFC signal (Fig. 4a, b). In a next step,
we analyzed correlations between DA release and volumes
of individual PFC sub-regions as implemented into
Freesurfer 6.0 software according to anatomical and
functional priors42. In perfect agreement with the vertex-
wise analysis, we observed the by far strongest correla-
tions in three anatomically adjacent left-hemispheric
regions: Brodmann areas (BA) 46 (dorsolateral pre-
frontal cortex; DLPFC), and BA 44 and BA 45, or pars
opercularis and triangularis of the left inferior frontal
gyrus (IFG), together forming “Broca’s area”49.
Plotting the correlations between volume of these
regions (henceforth referred to as DLPFC/IFG) and DA
release in the five subcortical ROIs (CAU, PUT, VST, GP,
and SNVTA in rostro-caudal anatomical order) revealed a
remarkable “herring bone”-like pattern (Fig. 5). This
pattern is shaped by negative regression lines—indicating
DLPFC/IFG-inhibition of DA release in HVUNSENS—and
positive regression lines observed after the same subjects
had undergone AMPH sensitization (HVUNSENS vs.
HVSENS vs. FEP: F(2;278.9))= 10.14, p= .00005). We did
not observe any significant relationships between sub-
cortical DA release and cortical volumes in FEP (Fig. 5).
To account for possible changes in brain volume induced
by AMPH sensitization, we derived volumetric para-
meters in an independent group of AMPH naïve, sex and
age matched HVs. There were no significant differences
between our group of HVSENS and the independent HV
group (Supplementary Fig. 6). Although of restricted
power, these results argue against gross volumetric effects
arising from our sensitization procedure.
Discussion
This study is the first to directly compare AMPH-
induced DA release in patients with FEP to DA release in
HV before and after prospective AMPH sensitization. Our
data confirm the main hypothesis of this work: subcortical
DA transmission in patients with FEP is in a state of
“endogenous sensitization” towards AMPH. They thus
replicate and extend the results of earlier studies that have
used D2/3 receptor antagonist-radioligands for studying
DA release in SCZ3–6 and the effects of AMPH sensiti-
zation in HV15. In contrast to these studies, we found no
relationship between DA release and change in positive
symptoms of SCZ. However, we observed a significant
Fig. 5 Relationship between volume of the dorsolateral
prefrontal cortex (in cm3) and inferior frontal gyrus (DLPFC/IFG)
as measured with magnetic resonance imaging and AMPH-
induced reductions in non-displaceable binding potential (BPND)
values of the dopamine D2/3 receptor positron emission
tomography (PET) radioligand [11C]-(+)-PHNO in healthy
subjects before and after sensitization to D-amphetamine
compared to patients with schizophrenia. Significant interactions
are found in brain regions (GP, SNVTA) where dopamine D3
(in contrast to D2) receptors are the predominant source of signal
detected with [11C]-(+)-PHNO and PET. VST, ventral striatum; GP,
globus pallidus; SNVTA, substantia nigra/ventral tegmental area.
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correlation between [11C]-(+)-PHNO BPND values after
AMPH in the putamen and negative symptoms, in par-
ticular emotional withdrawal. Although the interpretation
of this finding is not straightforward, the finding was
highly significant and is somewhat supported another
[11C]-(+)-PHNO study50 that found a negative relation-
ship between stress-induced DA release in SNVTA and
negative symptoms in individuals with clinical high risk
for schizophrenia (and at trend level, also patients with
FEP). Together, these results corroborate the notion that
reduced DA transmission is a relevant element in the
pathogenesis of negative schizophrenic symptoms.
Our results are at odds with those of a recent study
using the D2/3 receptor agonist radioligand [
11C]NPA47.
In contrast to our results and those obtained with D2/3
antagonist radioligands3–6, the study by Frankle et al.
study did not find enhanced AMPH-induced DA release
in schizophrenia. Besides differences in clinical variables
(as for example a smaller proportion of medication-naïve
patients in the Frankle et al. study), the discrepancy could
also reflect different properties of the two radioligands.
Since the method used in both studies does not allow for
reliably distinguishing between the absolute number of
receptors and receptor affinity (including changes in
apparent affinity induced by competition with endogen-
ous DA51), it remains open how these parameters exactly
relate to each other in dopaminergic dysfunction of
SCZ52.
Relationships between volumetric and functional data
suggest that AMPH-induced DA release in HV at first
exposure to the drug is under inhibitory control of the
left-hemispheric DLPFC/IFG. At the same time, AMPH
sensitization increased DA release to a greater extent in
subjects with larger DLPFC/IFG volumes. This relation-
ship was particularly pronounced in GP and SNVTA (Fig.
4), where the [11C]-(+)-PHNO signal is predominantly
reflecting binding to DA D3 rather than D2 receptor
subtypes53–55. Since it is unlikely, according to our data
obtained in an independent HV sample, that AMPH
sensitization had induced major volumetric changes, the
“herring bone” pattern most likely reflects a true func-
tional shift in control of subcortical DA release by the
DLPFC/IFG from inhibition in HVUNSENS towards facil-
itation in HVSENS. This interpretation is supported by
rodent data showing that expression of the sensitized state
is critically dependent on the integrity of PFC neuronal
tissue and its interaction with subcortical D3 receptors
56.
In our study, prospective sensitization of HV led to an
increase in DA release to the magnitude observed in FEP.
DLPFC/IFG volumes, while showing strong correlations
to DA release in HVUNSENS, did not show any significant
relationship to DA release in patients with FEP (Fig. 4).
While we cannot rule out that this is due to lack of power,
the very same region was found to show abnormal cortical
folding in SCZ patients with a mean illness duration of
two decades and extensive exposure to antipsychotics57.
Thus, our data support the long-standing conjecture that
the hyperdopaminergic state in SCZ is directly related to a
dysfunction in top-down control of subcortical DA
transmission by the PFC22,58, and they are consistent with
the notion that antipsychotics act by rectifying the con-
sequences of upstream pathogenic factors, which persist
despite antipsychotic treatment.
Antipsychotic-sensitive hyperlocomotion is a standard
measure for sensitization in rodents and a widely accepted
animal model of SCZ. Although not formally quantified in
this study, the most evident behavioral effect of AMPH in
our participants was an increase in quantitative speech
production. Thus, while expressing on a motor level in
rodents, enhanced DA transmission in human AMPH-
sensitive brain circuits seems to affect primarily neuronal
functions involved in the processing of language and
speech, making speech being the human equivalent to
rodent hyperlocomotion. Alterations in cytoarchitecture
introduced into the rodent PFC by disrupting the cytos-
keleton of dendritic spines increase subcortical DA levels
and induce hyper-locomotion via direct projections
between the PFC and SNVTA59. Similar alterations in the
DLPFC/IFG of patients with SCZ may cause dysfunctions
in hierarchical control within DLPFC/IFG—
SNVTA–striato-thalamic loops and may be involved in
mediating the autonomous (i.e., not subject to will) pro-
duction of language in auditory verbal hallucinations of
patients with SCZ. Simultaneously activated by certain
grammatical constructs60, altered interactions between
the DLPFC/IFG and the evolutionarily ancient SNVTA
may also be involved in generating the fascinating and
inherently grammatical symptom-complex of schizo-
phrenic “ego disturbances”.
As prospective AMPH sensitization in HV successfully
mimics the endophenotype of increased DA release
observed in “psychotic sensitization”, our data prompt the
question why the endophenotype associates with psy-
chotic symptoms in SCZ but is occurring—unless re-
exposed to AMPH—without any relevant behavioral
effects in HVs. Symptom-provocation studies61 and eco-
logical evidence strongly suggest this to be a matter of
dose and intensity of exposure: While an escalation of the
AMPH dose induces transient psychotic symptoms in
psychiatrically healthy subjects61, subjects with stimulant-
use disorders indeed exhibit disproportionally high
rates of psychotic disorders62. Interestingly, subjects
abusing methamphetamine or cocaine exhibit increased
[11C]-(+)-PHNO binding in the GP63,64. What seems to
differentiate AMPH-induced from “endogenous psycho-
tic” sensitization in our data—higher [11C]-(+)-PHNO
BPND values in GP—may just be a matter of dose and
length of exposure to AMPH.
Weidenauer et al. Translational Psychiatry            (2020) 10:2 Page 8 of 11
An inherent limitation of our method is that it does not
discriminate the effects of extracellular DA levels from
changes in maximal D2/3 receptor binding capacity. In
addition, although more sensitive towards fluctuations in
extracellular DA, the differences between HVs and FEP
patients observed with the agonist radioligand [11C]-
(+)-PHNO are by no means larger than those observed
with antagonist radioligands1–6. However, this could in
part also be a consequence of increased D2/3 receptor
occupancy due to higher baseline extracellular DA levels
in patients with FEP (Fig. 3b). Another limitation might be
the fact that some patients required benzodiazepines due
to agitation or anxiety. Although there was no significant
difference between medicated and unmedicated patients
we cannot rule out the possibility that this might be a
confounding factor. Furthermore, although sex did not
play a role when entered as a covariate, the imbalance
between male and female patients in the FEP sample has
to be mentioned as a limitation. Lastly, our design has the
limitation that we did not expose, mainly for ethical rea-
sons, our FEP patients to a sensitizing regime of repeated
AMPH. However, rarely cited earlier work by Strakowski
et al.65 has shown that FEP patients fail to show a pro-
gressive enhancement in the response to repeated AMPH.
This suggests that FEP patients, at least at the level of
behavior, are already maximally sensitized. Our data
support and extend this finding to a neurochemical level.
In summary, we feel confident that our work provides the
first direct experimental proof for the hypothesis that the
pathogenic substrate underlying psychosis in SCZ is
indeed a state of “endogenous sensitization” in subcortical
DA systems.
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